A TH2/eosinophil signature, which is inhibited by anti-IL5R (benralizumab) treatment in the peripheral blood of asthma patients [52] is upregulated in both CD and UC patients who do not attain remission at week 14. The gene discussed is IL5RA; the disease is asthma.